This is the first report of a natural recombination event occurring in the 5' genomic extremity of poliovirus, suggesting recombination between a vaccine-derived and a wild poliovirus.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to recombinant poliovirus risks after vaccination; leaves open frequency, transmissibility, and human impact.
Intertypic vaccine/vaccine recombinant polioviruses are frequently isolated from vaccine-associated paralytic poliomyelitis cases (VAPP). We identified a vaccine/nonvaccine poliovirus recombinant as the causative agent of a lethal VAPP. Partial RNA sequencing revealed a tripartite recombinant structure of the viral genome. This consisted of a central capsid core of vaccine origin flanked by two units of nonvaccine origin. The first nonvaccine genomic unit spanned the whole 5' noncoding region, and the second one almost the entire nonstructural protein-coding region and the 3' noncoding region. Amino acid and nucleotide sequence similarities in the 3' and 5' unidentified regions indicated that the viral donor(s) were poliovirus species, suggesting recombination between a vaccine-derived and a wild poliovirus. The nonvaccine donor(s) could not be identified among the investigated wild polioviruses cocirculating in the same geographical area. This is the first report of a natural recombination event occurring in the 5' genomic extremity of poliovirus. The neurovirulence for transgenic mice and the pathogenicity for humans of the recombinant suggested that the modular genomic organization of this virus might have conferred a selective advantage over its vaccine parent.
No takes yet. Share an insight, caveat, or question.
Georgescu et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: